We are live on ! Find out more
INDP icon

Indaptus Therapeutics
INDP

15 hedge funds and large institutions have $1.31M invested in Indaptus Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more capital invested

Capital invested by funds: $1.06M → $1.31M (+$254K)

0% more funds holding

Funds holding: 15 → 15 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.01% less ownership

Funds ownership: 0.26% → 0.25% (-0.01%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 6

Holders
15
Holders Change
–
Holders Change %
0%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$27K
2
JP Morgan Chase
JP Morgan Chase
New York
+$53

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$29.2K
2
State Street
State Street
Massachusetts
-$12.1K
3
Renaissance Technologies
Renaissance Technologies
New York
-$6.28K
4
UBS Group
UBS Group
Switzerland
-$3.35K
5
Morgan Stanley
Morgan Stanley
New York
-$1.65K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$574K – – –
IHL
2
Investment House LLC
California
$229K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$123K – – –
SAM
4
Strategy Asset Managers
California
$102K – – –
PVI
5
Pine Valley Investments
New Jersey
$98.9K -$160 -3 -0.2%
Renaissance Technologies
6
Renaissance Technologies
New York
$58K -$6.28K -118 -11%
VCM
7
Vivaldi Capital Management
Illinois
$51.6K – – –
VF
8
Virtu Financial
New York
$32K +$27K +508 New
State Street
9
State Street
Massachusetts
$29.3K -$12.1K -228 -33%
TRCT
10
Tower Research Capital (TRC)
New York
$9.11K -$1.23K -23 -14%
UBS Group
11
UBS Group
Switzerland
$4.34K -$3.35K -63 -48%
Morgan Stanley
12
Morgan Stanley
New York
$1.98K -$1.65K -31 -49%
BSB
13
Bangor Savings Bank
Maine
$896 – – –
Wells Fargo
14
Wells Fargo
California
$235 – – –
JP Morgan Chase
15
JP Morgan Chase
New York
$31 +$53 +1 New
Group One Trading
16
Group One Trading
Illinois
$16 – – –
Qube Research & Technologies (QRT)
17
Qube Research & Technologies (QRT)
United Kingdom
$2 – – –
Citadel Advisors
18
Citadel Advisors
Florida
– -$29.2K -590 Closed
Bank of America
19
Bank of America
North Carolina
– -$5 – –

INDP Hedge Fund Activity: Q1 2024 in Review

15 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q1 2024, worth a combined $1.31M — up 24% from $1.06M a quarter earlier.

Fund positioning in INDP was balanced in Q1 2024: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 6 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $27K. The largest seller was Citadel Advisors, exiting entirely with an estimated $29.2K sold.

  • 15 institutional investors held Indaptus Therapeutics (INDP) as of Q1 2024, unchanged from Q4 2023.
  • Funds reported $1.31M of Indaptus Therapeutics stock for Q1 2024, up 24% quarter-over-quarter.
  • 2 funds opened new Indaptus Therapeutics positions in Q1 2024 and 2 closed out, a net change of 0 holders.
  • The largest Indaptus Therapeutics buyer in Q1 2024 was Virtu Financial, an estimated $27K added.
  • The largest Indaptus Therapeutics seller in Q1 2024 was Citadel Advisors, an estimated $29.2K sold.

Based on aggregated 13F filings for Q1 2024.